Informing drug development in CNS disorders

AdisInsight ( is an integrated database of profiles authored by Springer Nature editors sourced from publicly available information from journals, conferences, trial registries, media releases, company websites, and government filings about pharmaceutical development programs, clinical trial studies, and published individual case safety reports.  Information in AdisInsight is updated daily to keep pace with the rapid pace of development in CNS disorders.

Download the Jinfo review about AdisInsight


Case studies

Access your copy of the AdisInsight therapy area case studies 2018

Clinical Trial Profiles

Key findings being reported from the clinical trials being conducted to move the drug programs profiled in the data base through international regulatory pathways.  Each clinical trial is profiled to allow quick assessment of the study results, study design, and study details.  Below is an example from the profile for Actelion Pharmaceuticals’ multicenter, randomized, double-blind, parallel-group extension to study AC-058B201 to investigate the long-term safety, tolerability, and efficacy of three doses of Ponesimod, an Oral S1P1 Receptor Agonist, in patients with relapsing-remitting multiple sclerosis. 

Drug Profiles

AdisInsight helps researchers understand the progress individual drug development programs are making in the treatment of CNS disorders. Each drug development program is tracked and summarized in a comprehensive drug profile with the aim of providing quick and easy access to the scientific and clinically important developments being reported from bench research to product launch.  See an excerpt from the AdisInsight drug profile for Pridopidine, which is in Phase III development for Huntington ’s disease.

View the full profile

View the full profile

Global Drug Pipeline

New Content Item

The database can show the current status of the global drug pipeline for CNS Disorder by aggregating the information across all 4,974 drugs in the data base that are either marketed, in regulatory approval, in clinical development, in preclinical development, or have been discontinued for the treatment of CNS disorders.

Global Clinical Trial Map

New Content Item

AdisInsight can be used to show where in the world clinical trials are actively studying drugs for the treatment of CNS disorders.  Some of these studies will be active in either the planning, recruitment, or administration stage while other will be inactive either completed or discontinued.  The clinical trial map shown below aggregates information across all 10,031 trials researching CNS drugs to show where active clinical development is taking place at a regional level.

Identifying Organizations

New Content ItemThe database can show which organizations are active in pursuing drug development treatment for CNS disorders.  This information can be valuable in identifying potential partners and/or acquisition targets.  The chart below draws information across all 4,974 drugs in development for CNS disorders to present a comprehensive view across all phases of development including marketing and discontinued programs.

Stay up to date

Follow us on Twitter

Here to foster information exchange with the library community

Follow us on Facebook

Springer Nature's LibraryZone is a community developed to foster sharing of information with the library community. Enjoy!

Connect with us on LinkedIn

Connect with us on LinkedIn and stay up to date with news and development.

Sign up for our alerts

News, information on our forthcoming books, author content and discounts.